Ceftriaxone Does NOT Reliably Cover Staphylococcus lugdunensis
Ceftriaxone should not be used as definitive therapy for S. lugdunensis infections; instead, use antistaphylococcal penicillins (nafcillin/oxacillin), cefazolin, or vancomycin (if methicillin-resistant). While S. lugdunensis is technically a coagulase-negative staphylococcus, it behaves clinically like S. aureus with similar virulence and requires treatment as such 1.
Why Ceftriaxone is Inadequate
The FDA label for ceftriaxone lists S. aureus and S. epidermidis as covered organisms for certain indications 2, but this coverage is problematic even for methicillin-susceptible Staphylococcus aureus (MSSA):
- Recent pharmacodynamic studies demonstrate ceftriaxone achieves minimal bacterial killing against MSSA even at high doses (2g twice daily), with only 1-log reduction in bacterial counts that plateaus without further killing 3
- Clinical outcomes are worse with ceftriaxone: A 2023 multicenter study showed ceftriaxone for MSSA bacteremia was associated with significantly higher 90-day treatment failure (HR 2.66,95% CI 1.15-6.12) compared to cefazolin or antistaphylococcal penicillins 4
- The MIC of ceftriaxone for staphylococci is typically 2-4 fold higher than for other susceptible organisms, making standard dosing inadequate 3
S. lugdunensis Requires S. aureus-Level Treatment
S. lugdunensis is unique among coagulase-negative staphylococci:
- It causes aggressive infections including endocarditis, bacteremia, and deep tissue infections with outcomes resembling S. aureus rather than typical CNS 1
- Antibiotic susceptibility testing should be interpreted using S. aureus breakpoints, not CNS breakpoints 5
- The single case report of successful cefotaxime treatment 1 involved a pediatric UTI with reflux—a less severe infection where high urinary drug concentrations may have compensated for marginal activity
Recommended Therapy
For methicillin-susceptible S. lugdunensis:
- First-line: Nafcillin or oxacillin 2g IV every 4-6 hours
- Alternative: Cefazolin 2g IV every 8 hours (preferred by many due to lower toxicity) 6
For methicillin-resistant S. lugdunensis:
- Vancomycin 15 mg/kg IV every 12 hours (dosed to trough 10-15 μg/mL) 6
Critical Pitfall to Avoid
Do not assume that because S. lugdunensis is coagulase-negative, it can be treated like S. epidermidis or dismissed as a contaminant. Its virulence demands aggressive, appropriate antistaphylococcal therapy from the outset to prevent mortality and morbidity from endocarditis, metastatic infection, or treatment failure.